Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.  

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review. Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... RNA viruses, today announced a research collaboration with ... testing of the Company,s lead compound, SB 9200, ... against which currently there are no effective antiviral ... proprietary Small Molecule Nucleic Acid Hybrid (SMNH) ...
(Date:9/18/2014)... ROCKVILLE, Md. , Sept. 18, 2014 ... a biotechnology company with fully integrated commercial and drug ... oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary focus on China , announce ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
(Date:9/18/2014)... New York, New York (PRWEB) September 18, 2014 ... dozen Xarelto lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending ... attempting to have all claims filed on behalf ... According to motions filed on September 11th, the ... and other claims contained in the lawsuits have ...
(Date:9/18/2014)... Kent, WA Chiropractor Danene Saggau and the ... that Dawn Kelly has agreed to become the new Office ... to Ms. Kelly expanding her role within the practice, noting ... key contributor. “ Dawn Kelly brings to the clinic ... that will allow me to focus on the patient ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a Board ... Facial Plastic and Reconstructive Surgery and a Professor at ... Plastic Surgery. He is recognized around the world ... Dr. Ellis will be presenting on numerous injectable topics. ... techniques and various treatments for complications associated with injectable ...
(Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
(Date:9/18/2014)... (HealthDay News) -- Exposure to diverse communities may boost ... Hearing different languages in the park or supermarket ... from people who are different from them, researchers found. ... are often biased against interacting with and learning from ... a University of Chicago psychology professor, said in a ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... , , , INDIANAPOLIS, ... been named by Adventist Health System as its exclusive clearinghouse ... utilize RealMed,s portal-based clearinghouse/Revenue Cycle Management Services to improve Adventist ... , , (Logo: ...
... , , , ... development-stage pharmaceutical company discovering and developing novel RNA interference ... Vice President, Pharmaceutical Development, will participate in multiple roles ... The conference will take place August 3-5, 2009 in ...
... , , HATBORO, Pa., ... IFLG ), a leading technology provider of enterprise ... the introduction of a new mobility offering for healthcare providers, ... solution that enables medical professionals to access critical patient information ...
... , , , ... August 3 Zogenix, Inc. ("Zogenix"), a privately held ... today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan ... approval in July 2009 and is a first-of-its-kind needle-free ...
... skills increase the risk of trouble, expert says, , MONDAY, ... ramping up physical education programs to battle the childhood obesity ... has risen dramatically, Ohio State University researchers report. , ... injuries related to physical education (PE) increased 150 percent -- ...
... published in the August issue of The Journal of ... an important tool for depicting the extent of neuroblastoma in ... the disease. Neuroblastoma accounts for six to ten percent of ... of cancer deaths in children. Accurately identifying where in the ...
Cached Medicine News:Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 2Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 3Health News:Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference 2Health News:Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference 3Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:Gym Class Injuries Up 150 Percent 2Health News:Gym Class Injuries Up 150 Percent 3Health News:PET can help guide treatment decisions for a common pediatric cancer 2
Bipolar foot activated forceps....
Bipolar forceps 6.7 cm 2-11/16" or 3/32" (bent) coated....
Blunt, with attached cable for Valleylab and other brands generators....
Blunt, 20 cm long....
Medicine Products: